PTC Therapeutics Authorizes Up To $500 Million Buyback, Calls Its Shares A 'Compelling Opportunity'
The rare-disease drugmaker's board approved the repurchase program days after it raised its 2026 revenue guidance.
PTC Therapeutics, a biopharmaceutical company that develops medicines for rare disorders, said Tuesday its board authorized the repurchase of up to $500 million of its common stock, subject to market conditions. The approval comes days after the company raised its full-year 2026 revenue guidance.
How the buyback can be executed
Management decides when and how to buy. The company said purchases may come through open-market transactions, including pre-set trading plans, as well as privately negotiated deals, accelerated repurchases and other transactions that comply with securities law.
Results of any buying will show up in the company's quarterly 10-Q and annual 10-K reports, the 8-K says.
Klein's "compelling opportunity" pitch
CEO Matthew B. Klein said in the company's announcement that the program reflects "deep conviction in the strength of the Company and the prospects for near- and long-term growth."
He added that PTC is investing in itself "at a time when our shares provide a compelling opportunity" while keeping the financial flexibility to support existing programs and pursue business development deals.
Raised guidance, Sephience launch
The authorization follows PTC's third-quarter report, in which it lifted 2026 total revenue guidance to $1.29 billion to $1.32 billion, led by the Sephience launch. Sephience revenue was $182 million in the quarter, the company reported on October 29. Klein said then that PTC was on track to reach cash flow breakeven this year.
Sephience treats phenylketonuria (PKU) and is approved in the United States, the European Economic Area and Japan, according to the company's annual report. PTC also sells Translarna and Emflaza for Duchenne muscular dystrophy, and receives Evrysdi revenue through its collaboration with Roche and the SMA Foundation. Its Huntington's disease drug votoplam is now led by Novartis.
PTC's shares trade on the Nasdaq Global Select Market under PTCT.
Sources
- 8-K Filing — PTC THERAPEUTICS, INC. (PTCT) — SEC EDGAR
- Exhibit tmb-ex99d1.htm — PTC THERAPEUTICS, INC. 8-K exhibit — SEC EDGAR
- PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program — prnewswire.com
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results — prnewswire.com